{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:11:14Z","timestamp":1791850274313,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Toronto Undergraduate Research Fund; University of Toronto Excellence Award in Natural Sciences and Engineering"},{"DOI":"10.13039\/100013301","name":"Parkinson&apos;s Foundation","doi-asserted-by":"publisher","award":["PF-PRF-933478"],"award-info":[{"award-number":["PF-PRF-933478"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["T32ES007322"],"award-info":[{"award-number":["T32ES007322"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2018-06409"],"award-info":[{"award-number":["RGPIN-2018-06409"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01ES023839"],"award-info":[{"award-number":["R01ES023839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U18DA052498"],"award-info":[{"award-number":["U18DA052498"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["391676"],"award-info":[{"award-number":["391676"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["407961"],"award-info":[{"award-number":["407961"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vesicular monoamine transporter 2 (VMAT2) is an essential transporter that regulates brain monoamine transmission and is important for mood, cognition, motor activity, and stress regulation. However, VMAT2 remains underexplored as a pharmacological target. In this study, we report that tricyclic and tetracyclic antidepressants acutely inhibit, but persistently upregulate VMAT2 activity by promoting VMAT2 protein maturation. Importantly, the VMAT2 upregulation effect was greater in BE(2)-M17 cells that endogenously express VMAT2 as compared to a heterologous expression system (HEK293). The net sustained effect of tricyclics and tetracyclics is an upregulation of VMAT2 activity, despite their acute inhibitory effect. Furthermore, imipramine and mianserin, two representative compounds, also demonstrated rescue of nine VMAT2 variants that cause Brain Monoamine Vesicular Transport Disease (BMVTD). VMAT2 upregulation could be beneficial for disorders associated with reduced monoamine transmission, including mood disorders and BMVTD, a rare but often fatal condition caused by a lack of functional VMAT2. Our findings provide the first evidence that small molecules can upregulate VMAT2 and have potential therapeutic benefit for various neuropsychiatric conditions.<\/jats:p>","DOI":"10.1038\/s41386-024-01914-2","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T17:10:41Z","timestamp":1722013841000},"page":"1783-1791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7346-4215","authenticated-orcid":false,"given":"Xunan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-8939","authenticated-orcid":false,"given":"Ilias","family":"Marmouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S. B.","family":"Finnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan L.","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanye","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin Q.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"St\u00f8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Lipina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2717-5279","authenticated-orcid":false,"given":"Amy J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-1284","authenticated-orcid":false,"given":"Gary W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salahpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","volume":"39","author":"MO Klein","year":"2019","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39:31\u201359.","journal-title":"Cell Mol Neurobiol"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.pa.13.040173.001145","volume":"13","author":"TN Chase","year":"1973","unstructured":"Chase TN, Murphy DL. Serotonin and central nervous system function. Annu Rev Pharm. 1973;13:181\u201397.","journal-title":"Annu Rev Pharm"},{"key":"1914_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00441-017-2649-1","volume":"373","author":"EE Benarroch","year":"2018","unstructured":"Benarroch EE. Locus coeruleus. Cell Tissue Res. 2018;373:221\u201332.","journal-title":"Cell Tissue Res"},{"issue":"Suppl 6","key":"1914_CR4","first-page":"7","volume":"61","author":"PL Delgado","year":"2000","unstructured":"Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61 Suppl 6:7\u201311.","journal-title":"J Clin Psychiatry"},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","volume":"19","author":"JR Strawn","year":"2018","unstructured":"Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19:1057\u201370.","journal-title":"Expert Opin Pharmacother"},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"10993","DOI":"10.1073\/pnas.89.22.10993","volume":"89","author":"JD Erickson","year":"1992","unstructured":"Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA. 1992;89:10993\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1914_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuint.2013.12.003","volume":"73","author":"AI Bernstein","year":"2014","unstructured":"Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014;73:89\u201397.","journal-title":"Neurochem Int"},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.gim.2022.09.010","volume":"25","author":"K Saida","year":"2023","unstructured":"Saida K, Maroofian R, Sengoku T, Mitani T, Pagnamenta AT, Marafi D, et al. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals. Genet Med. 2023;25:90\u2013102.","journal-title":"Genet Med"},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa1207281","volume":"368","author":"JJ Rilstone","year":"2013","unstructured":"Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368:543\u201350.","journal-title":"N Engl J Med"},{"key":"1914_CR10","doi-asserted-by":"crossref","unstructured":"Valli M, Cho SS, Uribe C, Masellis M, Chen R, Mihaescu A, et al. VMAT2 availability in Parkinson\u2019s disease with probable REM sleep behaviour disorder. Mol Brain. 2021;14:165.","DOI":"10.1186\/s13041-021-00875-7"},{"key":"1914_CR11","doi-asserted-by":"publisher","first-page":"1712.e9","DOI":"10.1016\/j.neurobiolaging.2012.12.020","volume":"34","author":"L Brighina","year":"2013","unstructured":"Brighina L, Riva C, Bertola F, Saracchi E, Fermi S, Goldwurm S, et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson\u2019s disease. Neurobiol Aging. 2013;34:1712.e9\u201313.","journal-title":"Neurobiol Aging"},{"key":"1914_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/903164","volume":"2015","author":"X Yang","year":"2015","unstructured":"Yang X, Xu P, Zhao Q, An R, Jia H, Liu Z, et al. Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson\u2019s disease in Han Chinese men. Parkinsons Dis. 2015;2015:1\u20138.","journal-title":"Parkinsons Dis"},{"key":"1914_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/hmg\/ddi445","volume":"15","author":"CE Glatt","year":"2006","unstructured":"Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet. 2006;15:299\u2013305.","journal-title":"Hum Mol Genet"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1056\/NEJM195412162512504","volume":"251","author":"ED Freis","year":"1954","unstructured":"Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251:1006\u20138.","journal-title":"N Engl J Med"},{"key":"1914_CR15","first-page":"884","volume":"71","author":"J Nick","year":"1955","unstructured":"Nick J. Melancholia in hypertensive patients caused by therapeutic use of Rauwolfia serpentina. Bull Mem Soc Med Hop Paris. 1955;71:884\u201393.","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"1914_CR16","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mu\u00f1oz F, \u00c1lamo C. History of the discovery of antidepressant drugs. Melatonin, Neuroprotective Agents and Antidepressant Therapy, New Delhi: Springer India; 2016. 365-83.","DOI":"10.1007\/978-81-322-2803-5_26"},{"key":"1914_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1021\/acschemneuro.5b00010","volume":"6","author":"KM Lohr","year":"2015","unstructured":"Lohr KM, Stout KA, Dunn AR, Wang M, Salahpour A, Guillot TS, et al. Increased vesicular monoamine transporter 2 (VMAT2; Slc18a2) protects against methamphetamine toxicity. ACS Chem Neurosci. 2015;6:790\u20139.","journal-title":"ACS Chem Neurosci"},{"key":"1914_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/toxsci\/kfw106","volume":"153","author":"KM Lohr","year":"2016","unstructured":"Lohr KM, Chen M, Hoffman CA, McDaniel MJ, Stout KA, Dunn AR, et al. Vesicular monoamine transporter 2 (VMAT2) level regulates MPTP vulnerability and clearance of excess dopamine in mouse striatal terminals. Toxicol Sci. 2016;153:79\u201388.","journal-title":"Toxicol Sci"},{"key":"1914_CR19","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1523\/JNEUROSCI.1301-06.2006","volume":"26","author":"T Sorkina","year":"2006","unstructured":"Sorkina T, Miranda M, Dionne KR, Hoover BR, Zahniser NR, Sorkin A. RNA interference screen reveals an essential role of Nedd4\u20132 in dopamine transporter ubiquitination and endocytosis. J Neurosci. 2006;26:8195\u2013205.","journal-title":"J Neurosci"},{"key":"1914_CR20","doi-asserted-by":"crossref","unstructured":"Bachman J Site-Directed Mutagenesis. Methods in Enzymology, 529, Elsevier; 2013. 241\u20138.","DOI":"10.1016\/B978-0-12-418687-3.00019-7"},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/acs.chemrestox.0c00380","volume":"34","author":"CA Black","year":"2021","unstructured":"Black CA, Bucher ML, Bradner JM, Jonas L, Igarza K, Miller GW. Assessing vesicular monoamine transport and toxicity using fluorescent false neurotransmitters. Chem Res Toxicol. 2021;34:1256\u201364.","journal-title":"Chem Res Toxicol"},{"key":"1914_CR22","doi-asserted-by":"publisher","first-page":"22053","DOI":"10.1074\/jbc.M116.749119","volume":"291","author":"P Beerepoot","year":"2016","unstructured":"Beerepoot P, Lam VM, Salahpour A. Pharmacological chaperones of the dopamine transporter rescue dopamine transporter deficiency syndrome mutations in heterologous cells. J Biol Chem. 2016;291:22053\u201362.","journal-title":"J Biol Chem"},{"key":"1914_CR23","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1073\/pnas.90.6.2542","volume":"90","author":"S Ramamoorthy","year":"1993","unstructured":"Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA. 1993;90:2542\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jchemneu.2016.11.003","volume":"83\u201384","author":"RA Cliburn","year":"2017","unstructured":"Cliburn RA, Dunn AR, Stout KA, Hoffman CA, Lohr KM, Bernstein AI, et al. Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. J Chem Neuroanat. 2017;83\u201384:82\u201390.","journal-title":"J Chem Neuroanat"},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/exnr.1998.7008","volume":"156","author":"GW Miller","year":"1999","unstructured":"Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in parkinson\u2019s disease. Exp Neurol. 1999;156:138\u201348.","journal-title":"Exp Neurol"},{"key":"1914_CR26","doi-asserted-by":"crossref","unstructured":"Green MR, Sambrook J. Purification of total RNA from mammalian cells and tissues. Cold Spring Harb Protoc. 2020;2020:db.prot101659.","DOI":"10.1101\/pdb.prot101659"},{"key":"1914_CR27","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/cb400259n","volume":"8","author":"G Hu","year":"2013","unstructured":"Hu G, Henke A, Karpowicz RJ Jr, Sonders MS, Farrimond F, Edwards R, et al. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2). ACS Chem Biol. 2013;8:1947\u201354.","journal-title":"ACS Chem Biol"},{"key":"1914_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1021\/acsptsci.0c00102","volume":"4","author":"S Bhat","year":"2021","unstructured":"Bhat S, Guthrie DA, Kasture A, El-Kasaby A, Cao J, Bonifazi A, et al. Tropane-based ibogaine analog rescues folding-deficient serotonin and dopamine transporters. ACS Pharm Transl Sci. 2021;4:503\u201316.","journal-title":"ACS Pharm Transl Sci"},{"key":"1914_CR29","doi-asserted-by":"publisher","first-page":"18524","DOI":"10.1074\/jbc.M112.343681","volume":"287","author":"S Bulling","year":"2012","unstructured":"Bulling S, Schicker K, Zhang Y-W, Steinkellner T, Stockner T, Gruber CW, et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem. 2012;287:18524\u201334.","journal-title":"J Biol Chem"},{"key":"1914_CR30","doi-asserted-by":"publisher","first-page":"19250","DOI":"10.1074\/jbc.M117.797092","volume":"292","author":"HMM Asjad","year":"2017","unstructured":"Asjad HMM, Kasture A, El-Kasaby A, Sackel M, Hummel T, Freissmuth M, et al. Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile\/juvenile parkinsonism. J Biol Chem. 2017;292:19250\u201365.","journal-title":"J Biol Chem"},{"key":"1914_CR31","doi-asserted-by":"publisher","first-page":"20876","DOI":"10.1074\/jbc.M116.737551","volume":"291","author":"A Kasture","year":"2016","unstructured":"Kasture A, El-Kasaby A, Sz\u00f6ll\u0151si D, Asjad HMM, Grimm A, Stockner T, et al. Functional rescue of a misfolded Drosophila melanogaster dopamine transporter mutant associated with a sleepless phenotype by pharmacological chaperones. J Biol Chem. 2016;291:20876\u201390.","journal-title":"J Biol Chem"},{"key":"1914_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jmd2.12030","volume":"47","author":"M Padmakumar","year":"2019","unstructured":"Padmakumar M, Jaeken J, Ramaekers V, Lagae L, Greene D, Thys C, et al. A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets. JIMD Rep. 2019;47:9\u201316.","journal-title":"JIMD Rep."},{"key":"1914_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86460-3","volume":"11","author":"K Soliman","year":"2021","unstructured":"Soliman K, Grimm F, Wurm CA, Egner A. Predicting the membrane permeability of organic fluorescent probes by the deep neural network based lipophilicity descriptor DeepFl-LogP. Sci Rep. 2021;11:6991.","journal-title":"Sci Rep."},{"key":"1914_CR34","doi-asserted-by":"crossref","unstructured":"Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, et al. Structure-activity relationships of dopamine transporter pharmacological chaperones. Front Cell Neurosci. 2022;16:832536.","DOI":"10.3389\/fncel.2022.832536"},{"key":"1914_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJM195301082480202","volume":"248","author":"RW Wilkins","year":"1953","unstructured":"Wilkins RW, Judson WE. The use of rauwolif serpentinain hypertensive patients. N Engl J Med. 1953;248:48\u201353.","journal-title":"N Engl J Med"},{"key":"1914_CR36","doi-asserted-by":"crossref","unstructured":"Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61 Suppl 6.","DOI":"10.4088\/JCP.v61n0201"},{"key":"1914_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","volume":"341","author":"E Jesulola","year":"2018","unstructured":"Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet? Behav Brain Res. 2018;341:79\u201390.","journal-title":"Behav Brain Res"},{"key":"1914_CR38","unstructured":"Ikram H, Haleem DJ. Repeated treatment with reserpine as a progressive animal model of depression. Pak J Pharm Sci. 2017;30:897\u2013902."},{"key":"1914_CR39","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1073\/pnas.1402134111","volume":"111","author":"KM Lohr","year":"2014","unstructured":"Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci USA. 2014;111:9977\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1914_CR40","unstructured":"Tofranil-PM\u00ae imipramine pamoate capsules. For oral administration. Fda.gov. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017090s74lbl.pdf. Accessed August 27, 2023."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01914-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:05:38Z","timestamp":1726218338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-01914-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.09.561601","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}